What is it about?
Transthyretin (TTR) is a transport protein that can misfold, break apart, and form dangerous amyloid fibrils in the heart, leading to progressive heart failure. I developed a mathematical model to test two competing hypotheses regarding this pathogenic process. The first theory suggests TTR proteins clump together in the bloodstream and then deposit into the heart, while the second suggests they travel to the heart first and form clumps directly inside the cardiac tissue. My model applies mass conservation equations to track the concentration of TTR tetramers, monomers, and oligomers over time. By simulating these two distinct biological pathways, the equations calculate the resulting volume of fibril deposits in the heart and the total TTR concentration in the blood plasma to see which scenario matches reality.
Featured Image
Photo by Ali Hajiluyi on Unsplash
Why is it important?
This model provides crucial mathematical evidence that TTR aggregation predominantly occurs directly within cardiac tissue rather than in the bloodstream. When simulating the tissue-aggregation scenario, the model successfully reproduces realistic clinical data, such as a patient survival time of five years and a normal blood TTR concentration of approximately 25 mg/dL. Conversely, simulating aggregation in the plasma predicted an impossible blood concentration of nearly 3000 mg/dL and significantly underestimated the heart damage. Additionally, this work introduces a novel biomarker for human biological age based on the volumetric ratio of deposited TTR fibrils compared to baseline myocardial volume. By confirming that the dissociation of TTR tetramers is the rate-limiting step in this disease, the model highlights exactly why stabilizing drugs like tafamidis are effective and pinpoints where future therapeutic interventions should be targeted to slow the aging of the heart.
Perspectives
Building this model allowed me to bridge the gap between abstract mathematical kinetics and the very real, progressive reality of cardiac amyloidosis. It is deeply rewarding to use theoretical biology not just to map equations, but to resolve a genuine medical debate about where exactly these toxic protein aggregates physically form in the human body. I hope this research demonstrates the practical power of computational modeling in clinical cardiology. By showing that amyloid burden can reach up to 58% of the heart's volume within five years, the math puts a stark, undeniable perspective on how aggressively this disease ages the heart, and I am optimistic these insights will guide faster, more targeted drug development.
Andrey V Kuznetsov
North Carolina State University
Read the Original
This page is a summary of: Does human transthyretin aggregate in blood plasma or in cardiac tissue? A mathematical modeling study, Journal of Theoretical Biology, November 2026, Elsevier,
DOI: 10.1016/j.jtbi.2026.112574.
You can read the full text:
Contributors
The following have contributed to this page
